Literature DB >> 1888803

Prevalence and severity of akathisia in patients on clozapine.

B M Cohen1, P E Keck, A Satlin, J O Cole.   

Abstract

The atypical antipsychotic clozapine is reported to have unique therapeutic effects and to produce minimal extrapyramidal side effects. However, in a blind survey, akathisia was observed to be similar in prevalence and severity in patients treated with clozapine and those receiving standard neuroleptic antipsychotic drugs. In addition, as with standard antipsychotic drugs, the presence of akathisia in patients receiving clozapine was associated with a worse overall clinical outcome. The results suggest that akathisia may be a common side effect of all antipsychotic drugs, that akathisia may be produced by a mechanism distinct from other locomotor effects of these medications, and that patients receiving clozapine, like patients receiving standard antipsychotic drugs, should be monitored for akathisia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1888803     DOI: 10.1016/0006-3223(91)90329-k

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  17 in total

Review 1.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

2.  Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.

Authors:  L Peacock; T Solgaard; H Lublin; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 4.  Managing antipsychotic-induced acute and chronic akathisia.

Authors:  C H Miller; W W Fleischhacker
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

5.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

6.  D1 receptor antagonists in schizophrenia.

Authors:  T R Barnes; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 7.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

8.  Extrapyramidal side effects of clozapine and haloperidol.

Authors:  M Kurz; M Hummer; H Oberbauer; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

9.  Clinical use of clozapine in a major urban setting: one year experience.

Authors:  E W Chow; E J Collins; S E Nuttall; A S Bassett
Journal:  J Psychiatry Neurosci       Date:  1995-03       Impact factor: 6.186

10.  Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys.

Authors:  D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.